Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Main Article Content

Andreas Wollenberg
Ludwig Maximilian University of Munich, Department of Dermatology and Allergy

Marjolein de Bruin-Weller
University Medical Center Utrecht Department of Dermatology

Jacob P Thyssen
Bispebjerg Hospital, University of Copenhagen, Department of Department of Dermatology

Lisa A Beck
Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center

Eric L Simpson
Oregon Health & Science University

Shinichi Imafuku
Fukuoka University Hospital

Mark Boguniewicz
Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health

Azra Kurbasic
Leo Pharma Inc.

Lise Soldbro
Leo Pharma Inc.

Natacha Strange Vest
Leo Pharma Inc.

Petra Arlert
Leo Pharma Inc.

Amy S Paller
Feinberg School of Medicine, Northwestern University

Keywords

atopic dermatitis, eczema, conjunctivitis, tralokinumab, phase 3, clinical trial, safety

References

1. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1

2. Simpson EL, et al. JAMA Dermatol. 2020;156:44–56

3. Thyssen JP, et al. J Am Acad Dermatol. 2017; 77: 280–86.e28

4. Wollenberg A, et al. Br J Dermatol. 2022;186:453–65

5. Akinlade B, et al. Br J Dermatol. 2019;181:459-73

6. Bieber T. Allergy. 2020;75:54–62

7. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480–89

8. Popovic B, et al. J Mol Biol. 2017;429:208–19

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.75

Article Details

How to Cite
[1]
Wollenberg, A., de Bruin-Weller, M., Thyssen, J.P., Beck, L.A., Simpson, E.L., Imafuku, S., Boguniewicz, M., Kurbasic, A., Soldbro, L., Strange Vest, N., Arlert, P. and Paller, A.S. 2022. Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s75. DOI:https://doi.org/10.25251/skin.6.supp.75.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 > >>